share_log

Johnson & Johnson | 10-K: FY2023 Annual Report

Johnson & Johnson | 10-K: FY2023 Annual Report

強生 | 10-K:2023財年年報
美股SEC公告 ·  02/16 16:19

Moomoo AI 已提取核心訊息

Johnson & Johnson (J&J) has reported a 6.5% increase in worldwide sales to $85.2 billion for the year 2023, compared to the previous year. U.S. sales saw a 10.6% rise, while international sales grew by 1.9%. The company's Innovative Medicine segment contributed $54.8 billion, up 4.2% from 2022, with significant growth in products like STELARA and TREMFYA. The MedTech segment also saw a 10.8% increase in sales to $30.4 billion, bolstered by acquisitions and operational growth. Despite these gains, J&J faces cybersecurity threats that could impact its business and financial condition. The company has established privacy compliance programs but acknowledges the risk of information security incidents. J&J also anticipates challenges following the separation of Kenvue Inc., including potential tax liabilities and the inability to predict Kenvue...Show More
Johnson & Johnson (J&J) has reported a 6.5% increase in worldwide sales to $85.2 billion for the year 2023, compared to the previous year. U.S. sales saw a 10.6% rise, while international sales grew by 1.9%. The company's Innovative Medicine segment contributed $54.8 billion, up 4.2% from 2022, with significant growth in products like STELARA and TREMFYA. The MedTech segment also saw a 10.8% increase in sales to $30.4 billion, bolstered by acquisitions and operational growth. Despite these gains, J&J faces cybersecurity threats that could impact its business and financial condition. The company has established privacy compliance programs but acknowledges the risk of information security incidents. J&J also anticipates challenges following the separation of Kenvue Inc., including potential tax liabilities and the inability to predict Kenvue's stock performance. The company's future plans include divesting its ownership interest in Kenvue, although the timing remains uncertain. J&J's Board of Directors has approved a share repurchase program, with $5.0 billion of common stock repurchased in fiscal 2023. The company's subsidiaries operate 61 manufacturing facilities worldwide, with a focus on maintaining these properties in good condition. J&J's executive officers have been elected by the Board to hold office for one year, with no family relationships or arrangements influencing their selection.
強生公司(J&J)報告稱,2023年全球銷售額增加6.5%至852億美元,相比上年增長。美國銷售額增長10.6%,而國際銷售增長1.9%。公司的創新藥業業務貢獻548億美元,較2022年增長4.2%,其中STELARA和TREMFYA等產品增長顯著。醫療技術部門的銷售額也增長了10.8%,達到304億美元,得益於收購和業務增長。儘管取得了這些收益,J&J面臨網絡安全威脅,可能會影響其業務和財務狀況。該公司已建立隱私合規計劃,但承認存在信息安全事件的風險。J&J還預計在Kenvue Inc.分離後面臨挑戰,包括潛在的稅務負債和無法預測Kenvue的股票表現。該公司未來的計劃包括出售其對Kenvue的所有權益,儘管時間尚不確定。J&J的董事會已批准回購計劃,回購50億美元的普通股票。該公司的子公司在全球運營着61個製造設施,並專注於保持這些財產的良好狀態。J&J的高管由董事會選舉,任期一年,沒有家族關係或安排影響其選擇。
強生公司(J&J)報告稱,2023年全球銷售額增加6.5%至852億美元,相比上年增長。美國銷售額增長10.6%,而國際銷售增長1.9%。公司的創新藥業業務貢獻548億美元,較2022年增長4.2%,其中STELARA和TREMFYA等產品增長顯著。醫療技術部門的銷售額也增長了10.8%,達到304億美元,得益於收購和業務增長。儘管取得了這些收益,J&J面臨網絡安全威脅,可能會影響其業務和財務狀況。該公司已建立隱私合規計劃,但承認存在信息安全事件的風險。J&J還預計在Kenvue Inc.分離後面臨挑戰,包括潛在的稅務負債和無法預測Kenvue的股票表現。該公司未來的計劃包括出售其對Kenvue的所有權益,儘管時間尚不確定。J&J的董事會已批准回購計劃,回購50億美元的普通股票。該公司的子公司在全球運營着61個製造設施,並專注於保持這些財產的良好狀態。J&J的高管由董事會選舉,任期一年,沒有家族關係或安排影響其選擇。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息